Genomic and Precision Medicine Oncology Third Edition
Melanoma
Publication
, Chapter
Farrow, NE; Therien, A; Tyler, DS; Beasley, GM
January 1, 2022
The treatment landscape for melanoma has dramatically changed in the last 9 years. The application of checkpoint blockade therapy and targeted therapies has driven improvements in survival for many patients with metastatic melanoma. Here, we review common molecular events that drive melanoma oncogenesis and review current molecular analysis that can guide individualized treatment plans.
Duke Scholars
Citation
APA
Chicago
ICMJE
MLA
NLM
Farrow, N. E., Therien, A., Tyler, D. S., & Beasley, G. M. (2022). Melanoma. In Genomic and Precision Medicine Oncology Third Edition (pp. 319–331). https://doi.org/10.1016/B978-0-12-800684-9.00005-8
Farrow, N. E., A. Therien, D. S. Tyler, and G. M. Beasley. “Melanoma.” In Genomic and Precision Medicine Oncology Third Edition, 319–31, 2022. https://doi.org/10.1016/B978-0-12-800684-9.00005-8.
Farrow NE, Therien A, Tyler DS, Beasley GM. Melanoma. In: Genomic and Precision Medicine Oncology Third Edition. 2022. p. 319–31.
Farrow, N. E., et al. “Melanoma.” Genomic and Precision Medicine Oncology Third Edition, 2022, pp. 319–31. Scopus, doi:10.1016/B978-0-12-800684-9.00005-8.
Farrow NE, Therien A, Tyler DS, Beasley GM. Melanoma. Genomic and Precision Medicine Oncology Third Edition. 2022. p. 319–331.